Loading...

ALLO ALLOGENE THERAPEUTICS INC Legal Disputes 8-K Filing

LLGN

LL

ALLOGENE THERAPEUTICS INC

(ALLO)

2025 8-K

Summary

Summary

Patent Infringement Case

Financial Update

Product Expansion

Financial Statements

Financial Results

Collaboration Expansion

Management Departure

Trial Enrollment Discontinued

Financial Results

Financial Results Announcement

Appointment of Principal Ac...

Merger of Equals

Financial Results Announcement

Financial Results Announcement

Accounting Restatement

Agreement with Notch Therap...

Collaboration Agreement

Safety Review Data

Financial Results Announcement

Appointment of CFO

Appointment of Executive Vi...

Financial Update

Data Presentation

Annual Meeting Results

Resignation of CFO

Data Presentation

Financial Update

Management Changes

Other Special Situation

Financial Results Announcement

Resignation of EVP

External Links:

On September 26, 2025, Allogene Therapeutics learned that Factor Bioscience is suing Cellectis for allegedly infringing its gene-editing patents, affecting Allogene's reliance on Cellectis’s TALEN technology. Allogene is not directly involved but is at risk if Factor pursues claims against them.

AI Assistant

ALLOGENE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.